US 11,912,784 B2
Methods of treating an eye disorder
Jason Ehrlich, Palo Alto, CA (US); Pablo Velazquez-Martin, Palo Alto, CA (US); Joel Naor, Palo Alto, CA (US); Daniel Victor Perlroth, Palo Alto, CA (US); and Hong Liang, Palo Alto, CA (US)
Assigned to Kodiak Sciences Inc., Palo Alto, CA (US)
Filed by Kodiak Sciences Inc., Palo Alto, CA (US)
Filed on Oct. 9, 2020, as Appl. No. 17/066,856.
Claims priority of provisional application 62/913,567, filed on Oct. 10, 2019.
Claims priority of provisional application 62/935,434, filed on Nov. 14, 2019.
Claims priority of provisional application 62/971,738, filed on Feb. 7, 2020.
Prior Publication US 2021/0107999 A1, Apr. 15, 2021
Int. Cl. A61K 39/395 (2006.01); A61K 9/00 (2006.01); A61K 47/58 (2017.01); A61K 47/68 (2017.01); A61P 27/02 (2006.01); C07K 16/22 (2006.01); C07K 17/08 (2006.01); A61K 39/00 (2006.01)
CPC C07K 17/08 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0048 (2013.01); A61K 47/605 (2017.08); A61K 47/6845 (2017.08); A61P 27/02 (2018.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01)] 43 Claims
 
1. A method of treating an eye disorder, comprising:
administering three loading doses of an anti-VEGF antibody conjugate to a subject in need of treating an eye disorder at a first loading dose, wherein the eye disorder is wet age-related macular degeneration (wAMD),
wherein the anti-VEGF antibody conjugate comprises:
an antibody conjugate comprising a light chain and a heavy chain, wherein the heavy chain comprises CDRH1: GYDFTHYGMN (SEQ ID NO: 9), CDRH2: WINTYTGEPTYAADFKR (SEQ ID NO: 10), and CDRH3: YPYYYGTSHWYFDV (SEQ ID NO: 11), and the light chain comprises CDRL1: SASQDISNYLN (SEQ ID NO: 12), CDRL2: FTSSLHS (SEQ ID NO: 13), and CDRL3: QQYSTVPWT (SEQ ID NO: 14), and wherein the heavy chain comprises an amino acid sequence at least 90% identical to SEQ ID NO: 1 and the light chain comprises an amino acid sequence at least 90% identical to SEQ ID NO: 2; and
a phosphorylcholine containing polymer covalently bonded to the heavy chain, wherein the polymer comprises 2-(methacryloyloxyethyl)-2′-(trimethylammonium)ethyl phosphate (MPC) monomers, and wherein the polymer has a molecular weight of between about 600,000 and about 1,000,000 Da
whereby the subject retains a therapeutic result of the anti-VEGF antibody conjugate therapy for at least 12 weeks after a final loading dose.